Your browser doesn't support javascript.
loading
Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial.
Ranjan, Tulika; Sengupta, Soma; Glantz, Michael J; Green, Richard M; Yu, Alexander; Aregawi, Dawit; Chaudhary, Rekha; Chen, Ricky; Zuccarello, Mario; Lu-Emerson, Christine; Moulding, Hugh D; Belman, Neil; Glass, Jon; Mammoser, Aaron; Anderson, Mark; Valluri, Jagan; Marko, Nicholas; Schroeder, Jason; Jubelirer, Steven; Chow, Frances; Claudio, Pier Paolo; Alberico, Anthony M; Lirette, Seth T; Denning, Krista L; Howard, Candace M.
Afiliação
  • Ranjan T; Department of Neuro-Oncology, Allegheny Health Network, Pittsburgh, PA, USA; Department of Neuro-Oncology, Cancer Center Southern Florida, Tampa General Hospital, Tampa, FL, USA.
  • Sengupta S; Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH, USA.
  • Glantz MJ; Department of Neurosurgery, Penn State Neuroscience Institute, Hershey, PA, USA.
  • Green RM; Department of Neuro-Oncology, Southern California Permanente Medical Group, Los Angeles, CA, USA.
  • Yu A; Department of Neurosurgery, Allegheny Health Network, Pittsburgh, PA, USA.
  • Aregawi D; Department of Neurosurgery, Penn State Neuroscience Institute, Hershey, PA, USA.
  • Chaudhary R; Department of Internal Medicine, Division of Hematology-Oncology, University of Cincinnati, Cincinnati, OH, USA.
  • Chen R; Department of Neuro-Oncology, Providence Brain & Spine Institute, Portland, OR, USA.
  • Zuccarello M; Department of Neurosurgery, University of Cincinnati, Cincinnati, OH, USA.
  • Lu-Emerson C; Department of Neuro-Oncology, Maine Medical Center, Scarborough, ME, USA.
  • Moulding HD; Department of Neuroscience, St. Luke's University Hospital & Health Network, Bethlehem, PA, USA.
  • Belman N; Department of Neuroscience, St. Luke's University Hospital & Health Network, Bethlehem, PA, USA.
  • Glass J; Departments of Neurology and Neurological Surgery, Thomas Jefferson University, Philadelphia, PA, USA.
  • Mammoser A; Department of Neurosurgery, LSU Health Sciences Center, New Orleans, LA, USA.
  • Anderson M; Department of Neurology, University of Mississippi Medical Center, Jackson, MS, USA.
  • Valluri J; Cordgenics, LLC, Huntington WV, USA.
  • Marko N; Department of Neurosurgery, LewisGale Regional Health System, Salem, VA, USA.
  • Schroeder J; Department of Neurosurgery, University of Toledo, Toledo, OH, USA.
  • Jubelirer S; Department of Neuro-Oncology, Charleston Area Medical Center, Charleston, WV, USA.
  • Chow F; Departments of Neurological Surgery and Neurology, University of Southern California, Los Angeles, CA, USA.
  • Claudio PP; Cordgenics, LLC, Huntington WV, USA; Department of Pharmacology & Toxicology, University of Mississippi Medical Center, Jackson, MS, USA.
  • Alberico AM; Department of Neurosurgery, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA.
  • Lirette ST; Department of Data Science, University of Mississippi Medical Center, Jackson, MS, USA.
  • Denning KL; Department of Pathology, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, USA.
  • Howard CM; Department of Radiology, University of Mississippi Medical Center, Jackson, MS, USA. Electronic address: cmhoward@umc.edu.
Cell Rep Med ; 4(5): 101025, 2023 05 16.
Article em En | MEDLINE | ID: mdl-37137304
ABSTRACT
Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors. In a randomized clinical trial (NCT03632135), the ChemoID assay, a personalized approach for selecting the most effective treatment from FDA-approved chemotherapies, improves the survival of patients with rGBM (2016 WHO classification) over physician-chosen chemotherapy. In the ChemoID assay-guided group, median survival is 12.5 months (95% confidence interval [CI], 10.2-14.7) compared with 9 months (95% CI, 4.2-13.8) in the physician-choice group (p = 0.010) as per interim efficacy analysis. The ChemoID assay-guided group has a significantly lower risk of death (hazard ratio [HR] = 0.44; 95% CI, 0.24-0.81; p = 0.008). Results of this study offer a promising way to provide more affordable treatment for patients with rGBM in lower socioeconomic groups in the US and around the world.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Cell Rep Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Cell Rep Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos